P Chalan1, G Di Dalmazi1,2, F Pani1,3, A De Remigis1,4, A Corsello1,5, P Caturegli6. 1. Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Ross Building-Room 656, 720 Rutland Avenue, Baltimore, MD, 21205, USA. 2. Division of Endocrinology, Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy. 3. Endocrinology Unit, Department of Medical Sciences and Public Health Endocrinology, University of Cagliari, Cagliari, Italy. 4. Department of Medicine, Arco Hospital, Trento, Italy. 5. Endocrine Tumor Unit, Department of General Medicine, San Raffaele Scientific Institute, Milan, Italy. 6. Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Ross Building-Room 656, 720 Rutland Avenue, Baltimore, MD, 21205, USA. pcat@jhmi.edu.
Abstract
BACKGROUND: Immunotherapy is a firmly established pillar in the treatment of cancer, alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like every treatment, also cancer immunotherapy causes a diverse spectrum of side effects, collectively referred to as immune-related adverse events. OBJECTIVE: This review will examine the main forms of immunotherapy, the proposed mechanism(s) of action, and the incidence of thyroid dysfunctions. METHODS: A comprehensive MEDLINE search was performed for articles published up to March 30, 2017. RESULTS: Following the pioneering efforts with administration of cytokines such as IL-2 and IFN-g, which caused a broad spectrum of thyroid dysfunctions (ranging in incidence from 1 to 50%), current cancer immunotherapy strategies comprise immune checkpoint inhibitors, oncolytic viruses, adoptive T-cell transfer, and cancer vaccines. Oncolytic viruses, adoptive T-cell transfer, and cancer vaccines cause thyroid dysfunctions only rarely. In contrast, immune checkpoint blockers (such as anti-CTLA-4, anti-PD-1, anti-PD-L1) are associated with a high risk of thyroid autoimmunity. This risk is highest for anti-PD-1 and increases further when a combination of checkpoint inhibitors is used. CONCLUSIONS: Cancer patients treated with monoclonal antibodies that block immune checkpoint inhibitors are at risk of developing thyroid dysfunctions. Their thyroid status should be assessed at baseline and periodically after initiation of the immunotherapy.
BACKGROUND: Immunotherapy is a firmly established pillar in the treatment of cancer, alongside the traditional approaches of surgery, radiotherapy, and chemotherapy. Like every treatment, also cancer immunotherapy causes a diverse spectrum of side effects, collectively referred to as immune-related adverse events. OBJECTIVE: This review will examine the main forms of immunotherapy, the proposed mechanism(s) of action, and the incidence of thyroid dysfunctions. METHODS: A comprehensive MEDLINE search was performed for articles published up to March 30, 2017. RESULTS: Following the pioneering efforts with administration of cytokines such as IL-2 and IFN-g, which caused a broad spectrum of thyroid dysfunctions (ranging in incidence from 1 to 50%), current cancer immunotherapy strategies comprise immune checkpoint inhibitors, oncolytic viruses, adoptive T-cell transfer, and cancer vaccines. Oncolytic viruses, adoptive T-cell transfer, and cancer vaccines cause thyroid dysfunctions only rarely. In contrast, immune checkpoint blockers (such as anti-CTLA-4, anti-PD-1, anti-PD-L1) are associated with a high risk of thyroid autoimmunity. This risk is highest for anti-PD-1 and increases further when a combination of checkpoint inhibitors is used. CONCLUSIONS:Cancerpatients treated with monoclonal antibodies that block immune checkpoint inhibitors are at risk of developing thyroid dysfunctions. Their thyroid status should be assessed at baseline and periodically after initiation of the immunotherapy.
Authors: Geoffrey T Gibney; Ragini R Kudchadkar; Ronald C DeConti; Melissa S Thebeau; Maria P Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J Schell; Kate J Fisher; Christine E Horak; H David Inzunza; Bin Yu; Alberto J Martinez; Ibrahim Younos; Jeffrey S Weber Journal: Clin Cancer Res Date: 2014-12-18 Impact factor: 12.531
Authors: Simon J Hall; Laurence Klotz; Allan J Pantuck; Daniel J George; James B Whitmore; Mark W Frohlich; Robert B Sims Journal: J Urol Date: 2011-07-23 Impact factor: 7.450
Authors: W H Kruit; R L Bolhuis; S H Goey; R L Jansen; A M Eggermont; D Batchelor; P I Schmitz; G Stoter Journal: J Clin Oncol Date: 1993-05 Impact factor: 44.544
Authors: Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Stephanie L Goff; Mark E Dudley; Deborah E Citrin; Robert P Somerville; John R Wunderlich; David N Danforth; Daniel A Zlott; James C Yang; Richard M Sherry; Udai S Kammula; Christopher A Klebanoff; Marybeth S Hughes; Nicholas P Restifo; Michelle M Langhan; Thomas E Shelton; Lily Lu; Mei Li M Kwong; Sadia Ilyas; Nicholas D Klemen; Eden C Payabyab; Kathleen E Morton; Mary Ann Toomey; Seth M Steinberg; Donald E White; Steven A Rosenberg Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: Inmaculada Peiró; Ramón Palmero; Pedro Iglesias; Juan José Díez; Andreu Simó-Servat; Juan Antonio Marín; Laura Jiménez; Eva Domingo-Domenech; Nuria Mancho-Fora; Ernest Nadal; Carlos Villabona Journal: Endocrine Date: 2019-02-25 Impact factor: 3.633
Authors: I Mazarico; I Capel; O Giménez-Palop; L Albert; I Berges; F Luchtenberg; Y García; L A Fernández-Morales; V J De Pedro; A Caixàs; M Rigla Journal: J Endocrinol Invest Date: 2019-05-15 Impact factor: 4.256
Authors: L Brilli; R Danielli; M Campanile; C Secchi; C Ciuoli; L Calabrò; T Pilli; A Cartocci; F Pacini; A M Di Giacomo; M G Castagna Journal: J Endocrinol Invest Date: 2020-12-26 Impact factor: 4.256